Last reviewed · How we verify
L-BLP25
At a glance
| Generic name | L-BLP25 |
|---|---|
| Also known as | MUC1-antibody |
| Sponsor | Prof. Dr. Carl Schimanski |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE2)
- Tecemotide (L-BLP25) in Prostate Cancer (PHASE2)
- L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (PHASE2)
- Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (PHASE3)
- Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (PHASE1)
- Tecemotide (L-BLP25) in Rectal Cancer (PHASE2)
- Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (PHASE3)
- Common Safety Follow-up Trial of Tecemotide (L-BLP25) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-BLP25 CI brief — competitive landscape report
- L-BLP25 updates RSS · CI watch RSS
- Prof. Dr. Carl Schimanski portfolio CI